{"nctId":"NCT00918138","briefTitle":"Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg","startDateStruct":{"date":"2009-08"},"conditions":["Type 2 Diabetes"],"count":219,"armGroups":[{"label":"Saxagliptin + Metformin XR + matching Metformin XR placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Metformin XR","Drug: Placebo matching Metformin XR"]},{"label":"Metformin XR + Metformin XR + matching Saxagliptin placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin XR","Drug: Placebo matching Saxagliptin"]}],"interventions":[{"name":"Saxagliptin","otherNames":["BMS-477118","Onglyza"]},{"name":"Metformin XR","otherNames":["Glucophage XR®"]},{"name":"Placebo matching Metformin XR","otherNames":[]},{"name":"Metformin XR","otherNames":["Glucophage XR®"]},{"name":"Placebo matching Saxagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes\n* 18-78 years of age\n* Taking stable dose of metformin immediate release (IR) or XR ≥850 mg and ≤1500 mg as monotherapy for at least 8 weeks prior to screening\n* Glycosylated hemoglobin A1C (A1C) 7.5-11.5% at screening\n* Fasting C-peptide: ≥1.0 ng/mL\n* FPG≥126 mg/dl obtained at the Day -7 visit\n* Body mass index (BMI): ≤ 40kg/m²\n* A1C ≥ 7.0% and ≤ 11.0% obtained at the Day -7 visit for randomization\n\nExclusion Criteria:\n\n* Women of childbearing potential unable or unwilling to use acceptable birth control\n* Women who are pregnant or breastfeeding\n* Significant cardiovascular history\n* Active liver disease\n* Renal impairment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4","description":"Adjusted mean change from baseline in MWG achieved with saxagliptin 5 mg plus metformin XR versus placebo plus metformin XR at Week 24. MWG was calculated as the area under the curve (AUC) for the full 24 hours expressed as average mg/dL. Glucose measurements were collected 30 minutes before and just prior to each meal (0 minutes) and 30, 60, 120, and 180 minutes after each meal (with 1 additional measurement at 240 minutes after the evening meal), midnight, 3 AM, and at end-of-domicile visit 24 hours after the first measurement. Mean change from baseline was adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191.3","spread":"6.26"},{"groupId":"OG001","value":"192.0","spread":"6.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173.2","spread":"5.85"},{"groupId":"OG001","value":"184.2","spread":"6.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":"5.69"},{"groupId":"OG001","value":"-8.2","spread":"5.96"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 4 in 2-hour Postprandial Glucose (PPG) (2 Hours After the Evening Meal)","description":"Adjusted mean change from baseline in 2-hour postprandial (after mealtime) plasma glucose two hours after start of the evening meal during 24-hour domicile visits evaluated both at pre-randomization (baseline) and at Week 4. Mean change from baseline was adjusted for baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"229.7","spread":"9.07"},{"groupId":"OG001","value":"234.0","spread":"10.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195.3","spread":"7.99"},{"groupId":"OG001","value":"228.1","spread":"11.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.4","spread":"9.69"},{"groupId":"OG001","value":"-0.2","spread":"10.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal","description":"FPG measurements were done at baseline, day 14 and 28. At baseline and day 28, the FPG value=plasma glucose value collected 30 minutes prior to the morning meal during the domicile visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.9","spread":"4.84"},{"groupId":"OG001","value":"164.2","spread":"5.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155.2","spread":"6.49"},{"groupId":"OG001","value":"161.8","spread":"5.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.3","spread":"5.93"},{"groupId":"OG001","value":"-3.6","spread":"6.17"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants With Confirmed Hypoglycemia Events During the Treatment Period","description":"'Confirmed' = recorded on the hypoglycemia AE case report form with a fingerstick for glucose \\<= 50 mg/dL and associated symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Participants With Reported Hypoglycemic Adverse Events During Treatment Period","description":"Hypoglycemic events are based upon the Saxagliptin Predefined List of Events, which includes hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. The Hypoglycemic events occurred in less than 5% of the participants and hence do not appear in the adverse events module.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["COUGH"]}}}